MARKET

VSTM

VSTM

Verastem
NASDAQ
4.395
+0.105
+2.45%
Opening 13:45 05/29 EDT
OPEN
4.280
PREV CLOSE
4.290
HIGH
4.405
LOW
4.220
VOLUME
789.15K
TURNOVER
--
52 WEEK HIGH
11.25
52 WEEK LOW
4.000
MARKET CAP
386.20M
P/E (TTM)
-1.7544
1D
5D
1M
3M
1Y
5Y
1D
Verastem files Form 3 initial beneficial ownership statement for director Michael P. Bailey
PUBT · 1d ago
Verastem Oncology to present at Jefferies Global Healthcare Conference fireside chat
PUBT · 2d ago
Verastem Oncology to Present at Jefferies Healthcare Conference
Barchart · 2d ago
H.C. Wainwright Sticks to Their Buy Rating for Verastem (VSTM)
TipRanks · 3d ago
Small-cap healthcare stocks ranked by quant ratings after earnings season
Seeking Alpha · 3d ago
Verastem Shareholders Back Board, Executive Pay and Plans
TipRanks · 3d ago
Verastem shareholders approve amended 2021 equity incentive plan at annual meeting
PUBT · 3d ago
*Verastem: Robert Gagnon Stepped Down From Board Following End of Term on May 21 >VSTM
Dow Jones · 3d ago
More
About VSTM
Verastem, Inc. is a late-stage development biopharmaceutical company, which focuses on the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (RAS)/ mitogen-activated pathway kinase (MAPK) pathway-driven cancers. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.

Webull offers Verastem Inc stock information, including NASDAQ: VSTM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VSTM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VSTM stock methods without spending real money on the virtual paper trading platform.